Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Foreign Generics See Ripe Market In Price Conscious Japan

This article was originally published in PharmAsia News

Executive Summary

Generic makers in other countries are setting their sights on Japan as the place for major expansions. Israel's Teva Pharmaceutical Industries and India's Ranbaxy Laboratories are among companies that plan to take advantage of the Japanese government's initiative to reduce the price of prescriptions. Ranbaxy has been trying to gain ground in Japan's market since it teamed with Nippon Chemiphar six years ago, but now it hopes to gain ground with its amlodipine generic of Pfizer's blockbuster Norvasc blood pressure drug. Other foreign generics planning expansions include Sandoz of Germany and Zydus Cadila of India. (Click here for more - a subscription may be required



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts